Sarepta Therapeutics Azioni (NASDAQ: SRPT)

Ultime notizie per Sarepta Therapeutics (NASDAQ:SRPT) Azioni

Sarepta Therapeutics

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585aa876b5a482000151d0ee/kevin-grundy">Exane BNP Paribas analyst Kevin Grundy</a> initiated coverage on Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Neutral rating and announced a price target of $261. Constellation Brands shares closed at $239.66 on Friday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen analyst Joseph Thome initiated coverage on Viridian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy rating. Viridian Therapeutics shares closed at $20.20 on Friday. <a href="https://www.benzinga.com/quote/VRDN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity analyst Edward Nash initiated coverage on Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) with a Buy rating and announced a price target of $89. Apogee Therapeutics shares closed at $43.46 on Friday. <a href="https://www.benzinga.com/quote/APGE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst Timothy Arcuri initiated coverage on Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Buy rating and announced a price target of $160. ARM shares closed at $135.99 on Friday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Mitchell Kapoor initiated coverage on Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announced a price target of $80. Sarepta Therapeutics shares closed at $114.23 on Friday. <a href="https://www.benzinga.com/quote/srpt/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SRPT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="621" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-1024x621.png" alt="" class="wp-image-663414" style="width:645px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-1024x621.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25085724/image-268.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

APGE

SRPT

VRDN

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

14 analysts have expressed a variety of opinions on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of $205.00, and a low estimate of $80.00. Experiencing a 5.56% decline, the current average is now lower than the previous average price target of $178.73. 
<img src="https://www.benzinga.com/files/images/story/2024/1732539677_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Sarepta Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Sell</td>
<td>$80.00</td>
<td>-</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$193.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$167.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$179.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>Discovering Sarepta Therapeutics: A Closer Look</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
<h3>Understanding the Numbers: Sarepta Therapeutics's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Sarepta Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 40.79% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sarepta Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of 7.19%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.93%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sarepta Therapeutics's ROA excels beyond industry benchmarks, reaching 0.96%. This signifies efficient management of assets and strong financial health.
Debt Management: Sarepta Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.14.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Sarepta Therapeutics's Future

HC Wainwright &amp; Co. analyst Mitchell Kapoor initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Sell rating and announces Price Target of $80.

Price Target

HC Wainwright & Co. Initiates Coverage On Sarepta Therapeutics with Sell Rating, Announces Price Target of $80

Guggenheim analyst Whitney Ijem maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and raises the price target from $148 to $150.

Guggenheim Maintains Buy on Sarepta Therapeutics, Raises Price Target to $150

Baird analyst Brian Skorney maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $200 to $193.

Baird Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $193

Evercore ISI Group analyst Gavin Clark-Gartner maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and lowers the price target from $179 to $170.

Evercore ISI Group Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $170

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) price target from $271 to $351. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Duolingo shares closed at $318.85 on Wednesday. See how other analysts view this stock.</li>
<li>B of A Securities cut the price target for Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) from $8 to $7. B of A Securities analyst Julien Dumoulin-Smith maintained an Underperform rating. Bloom Energy shares closed at $10.97 on Wednesday. <a href="https://www.benzinga.com/quote/BE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Vertex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) from $45 to $60. Needham analyst Joshua Reilly maintained a Buy rating. Vertex shares closed at $49.76 on Wednesday. <a href="https://www.benzinga.com/quote/VERX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $531 to $688. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. McKesson shares settled at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen raised Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) price target from $47 to $53. TD Cowen analyst Andrew Charles maintained a Buy rating. Dutch Bros shares closed at $34.94 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities cut Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) price target from $49 to $43. Truist Securities analyst Neal Dingmann downgraded the stock from Buy to Hold. Devon Energy shares closed at $40.02 on Wednesday. <a href="https://www.benzinga.com/quote/DVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from $152 to $167. Cantor Fitzgerald analyst Kristen Kluska upgradd the stock from Neutral to Overweight. Sarepta shares settled at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners raised Zymeworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) price target from $10 to $25. Leerink Partners analyst Andrew Berens upgraded the stock from Market Perform to Outperform. Zymeworks shares closed at $15.61 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital slashed the price target for Crocs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NYSE">CROX</a>) from $150 to $110. Loop Capital analyst Laura Champine downgraded the stock from Buy to Hold. Crocs shares closed at $102.74 on Wednesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods increased Lemonade, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) price target from $18 to $21. Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith downgraded the stock from Market Perform to Underperform. Lemonade shares closed at $29.29 on Wednesday. <a href="https://www.benzinga.com/quote/LMND/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

BROS

CROX

DUOL

LMND

VERX

ZYME

Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday

General

Sarepta Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results. Also, Cantor Fitzgerald upgraded the stock from Neutral to Overweight and raided its price target from $152 to $167.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded the rating for McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raised the price target from $531 to $688. McKesson shares closed at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded United States Cellular Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) from Market Perform to Outperform and announced a price target of $86. United States Cellular shares closed at $65.15 on Wednesday. <a href="https://www.benzinga.com/quote/USM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00b6e13513fb0001f03e9b/kristen-kluska">Cantor Fitzgerald analyst Kristen Kluska</a> upgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Overweight and boosted the price target from $152 to $167. Sarepta Therapeutics shares closed at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev upgraded Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Neutral to Overweight and raised the price target from $23 to $33. Clearwater Analytics shares closed at $28.58 on Wednesday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Steven Cahall upgraded the rating for Sinclair, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) from Underweight to Equal-Weight and increased the price target from $13 to $19. Sinclair shares closed at $17.41 on Wednesday. <a href="https://www.benzinga.com/quote/SBGI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MCK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png" alt="" class="wp-image-635130" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Upgrades

CWAN

SBGI

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Cantor Fitzgerald analyst Kristen Kluska upgrades Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Overweight and raises the price target from $152 to $167.

Cantor Fitzgerald Upgrades Sarepta Therapeutics to Overweight, Raises Price Target to $167

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy and maintains $205 price target.

Reiteration

Needham Reiterates Buy on Sarepta Therapeutics, Maintains $205 Price Target

WIIM

Sarepta Therapeutics shares are trading lower. The company reported Q3 financial results.

Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $(0.13) by 576.92 percent. This is a 100 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $467.172 million which beat the analyst consensus estimate of $409.297 million by 14.14 percent. This is a 40.79 percent increase over sales of $331.817 million the same period last year.

Earnings

Earnings Beats

Sarepta Therapeutics Q3 2024 Adj. EPS $0.62 Beats $(0.13) Estimate, Sales $467.172M Beat $409.297M Estimate.

In the latest quarter, 16 analysts provided ratings for Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $177.25, a high estimate of $205.00, and a low estimate of $150.00. This current average represents a 4.15% decrease from the previous average price target of $184.92. 
<img src="https://www.benzinga.com/files/images/story/2024/1729540841_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Sarepta Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$203.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$182.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Sarepta Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sarepta Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>Discovering Sarepta Therapeutics: A Closer Look</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
<h3>A Deep Dive into Sarepta Therapeutics's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Sarepta Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 38.93%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.78%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sarepta Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.63%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Sarepta Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.19%, the company showcases efficient use of assets and strong financial health.
Debt Management: Sarepta Therapeutics's debt-to-equity ratio is below the industry average at 1.27, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights

RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Outperform and maintains $182 price target.

RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $182 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586cf168351b9b0001a30551/nicole-deblase">Deutsche Bank analyst Nicole Deblase</a> initiated coverage on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Buy rating and announced a price target of $354. GE Vernova shares closed at $272.72 on Friday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Tim Rezvan initiated coverage on BKV Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) with an Overweight rating and announced a price target of $23. Prologis shares closed at $18.45 on Friday. <a href="https://www.benzinga.com/quote/BKV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Andrew Tsai initiated coverage on Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy rating and announced a price target of $165. Sarepta Therapeutics shares closed at $127.08 on Friday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58a5e02a43eaaa00018d93a0/josh-sullivan">Benchmark analyst Josh Sullivan</a> initiated coverage on ESCO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) with a Buy rating and announced a price target of $150. ESCO Technologies shares closed at $126.20 on Friday. <a href="https://www.benzinga.com/quote/ESE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst David Macdonald initiated coverage on Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) with a Buy rating and announced a price target of $22. Guardian Pharmacy shares closed at $17.68 on Friday. <a href="https://www.benzinga.com/quote/GRDN/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think:
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41421321/dow-s-p-500-settle-at-record-high-levels-record-6th-consecutive-week-of-gains-fear-index-moves-to-e">Dow, S&amp;P 500 Settle At Record High Levels, Record 6th Consecutive Week Of Gains: Fear Index Moves To &#8216;Extreme Greed&#8217; Zone</a></li>
</ul>

GRDN

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

15 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $176.93, along with a high estimate of $205.00 and a low estimate of $150.00. This current average represents a 4.45% decrease from the previous average price target of $185.17. 
<img src="https://www.benzinga.com/files/images/story/2024/1729512048_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sarepta Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Tsai</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$182.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$181.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$181.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$152.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Gavin Clark-Gartner</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$203.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$182.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sarepta Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Sarepta Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sarepta Therapeutics analyst ratings.</a>
<h2>Delving into Sarepta Therapeutics's Background</h2>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
<h3>Sarepta Therapeutics: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sarepta Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 38.93%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sarepta Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of 1.78%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.63%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.19%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.27.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 15 Analyst Insights On Sarepta Therapeutics

Jefferies analyst Andrew Tsai initiates coverage on Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Buy rating and announces Price Target of $165.

Jefferies Initiates Coverage On Sarepta Therapeutics with Buy Rating, Announces Price Target of $165

A coalition of unions, consumer groups, and public interest organizations has written to Lina Khan, Chair of the Federal Trade Commission (FTC), voicing strong opposition to Novo Holdings&#8217; proposed <a target="_blank" href="https://www.benzinga.com/news/24/02/36986742/catalents-bloomington-plant-making-novo-nordisks-obesity-drug-faces-fda-scrutiny-regarding-drug-manu" rel="noreferrer noopener">$16.5 billion acquisition</a> of Catalent Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>).
The groups <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrmlxkzpe/Consumer%20and%20Union%20Letter%20on%20Novo%20Catalent-10.17.24.pdf" rel="noreferrer noopener">argue</a> that the deal, which would unite the Danish pharmaceutical giant and dominant player in GLP-1 drug development, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), with Catalent, a leading global contract development and manufacturing organization (CDMO), could harm competition in critical areas such as diabetes, obesity treatments, and gene therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p" rel="noreferrer noopener">Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names</a>.
The letter outlines concerns that the acquisition could lead to &#8220;vertical foreclosure,&#8221; limiting access for Novo&#8217;s current and future rivals in GLP-1 drugs and gene therapies.
Catalent, with its 50 global facilities, has been an industry leader in manufacturing GLP-1 drugs, including Novo&#8217;s own Ozempic and Wegovy.
Since 2017, Catalent has been one of the few CDMOs capable of providing the specialized fill-finish development and manufacturing services essential for GLP-1 therapies.
By acquiring Catalent, Novo would have the power and incentive to restrict other pharmaceutical companies from accessing these vital services, potentially diminishing competition in this critical drug category.
The letter also highlights Catalent&#8217;s significance in gene therapy manufacturing, particularly in producing treatments like Sarepta Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) Elevidys and Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Zolgensma.
Many of Catalent&#8217;s facilities focus on cell and gene therapies, and the coalition believes that Novo&#8217;s acquisition could disrupt the production and development of these treatments.
In summary, the coalition argues that keeping Catalent independent is vital for fostering innovation and maintaining competition in the pharmaceutical industry.
An independent Catalent would support future competitors to Novo in both GLP-1 drugs and gene therapies, ensuring that patients continue to have access to life-saving treatments without market limitations driven by consolidation.
Last week, United States Senator Elizabeth Warren wrote a letter to FTC&#8217;s Lina Khan, urging her to investigate the deal&nbsp;thoroughly, amid growing concerns about&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41277809/ftc-faces-pressure-to-block-novo-nordisk-catalent-merger-over-antitrust-fears" rel="noreferrer noopener">potential antitrust violations</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41403897/whats-going-on-with-trump-media-technology-group-stock-on-friday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Trump Media &amp; Technology Group Stock On Friday?</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

CTLT

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and Do...

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)

JPMorgan sees a long-term buying opportunity after Sarepta (SRPT) shares were under pressure last week post earnings. Near-term, if one believes th...

Sarepta recent weakness brings buying opportunity, says JPMorgan

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

In a report released yesterday, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Repor...

Buy Rating on Sarepta Therapeutics: Confidence in Elevidys' Market Potential and Strategic Expansion

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target ...

TD Cowen Remains a Buy on Sarepta Therapeutics (SRPT)

High Alpha stocks that are rated 'overweight' – MS

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price target of $197.0...

J.P. Morgan Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Sarepta (SRPT) with a Sell rating and $80 price target The firm considers Elevidys co...

Sarepta initiated with a Sell at H.C. Wainwright

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Block, Five Below downgraded: Wall Street's top analyst calls

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Macy's (M) delayed its Q3 earnings rel...

Macy's uncovers employee fraud, Summit to be acquired: Morning Buzz

AAPL

ABBV

ANET

AVGO

BBIO

BBWI

BHVN

BIDU

CDNS

CMCSA

COST

CRGO

CTVA

DCGO

DELL

ENLC

ESTC

FANG

FIVE

FSLR

FTNT

GASS

GOOGL

HOOD

HUBS

INTC

KODK

LOVFF

LPLA

MARA

MSCI

MSFT

NDAQ

NFLX

NTNX

NVDA

PANW

PARA

PARAA

REGN

RIVN

SNOW

SNPS

SPOT

SPSC

SRRK

TEAM

TMUS

TRGP

TSLA

Press Releases

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

Comments

Sarepta Therapeutics

Notizie

Ultime notizie per Sarepta Therapeutics (NASDAQ:SRPT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO